Katarina Alenas - Nanologica VP Chromatography
| NICA Stock | 1.78 0.01 0.56% |
Insider
Katarina Alenas is VP Chromatography of Nanologica AB
| Age | 53 |
| Phone | 46 8 41 07 49 49 |
| Web | https://www.nanologica.com |
Nanologica Management Efficiency
The company has return on total asset (ROA) of (0.2514) % which means that it has lost $0.2514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8854) %, meaning that it generated substantial loss on money invested by shareholders. Nanologica's management efficiency ratios could be used to measure how well Nanologica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nis Kruse | BioPorto | N/A | |
| JeanChristophe May | Bavarian Nordic | 56 | |
| Henrik MSc | Bavarian Nordic | 58 | |
| Anu Kerns | Bavarian Nordic | 51 | |
| Christopher Bird | BioPorto | N/A | |
| Neil CPA | BioPorto | 55 | |
| Laurence Moerlooze | Bavarian Nordic | 59 | |
| Paul MSc | Bavarian Nordic | 56 | |
| Lars Uttenthal | BioPorto | N/A | |
| Gry Larsen | BioPorto | N/A | |
| Tony Summerlin | cBrain AS | N/A | |
| Anthony Pare | BioPorto | 60 | |
| Ejvindgensen | cBrain AS | N/A | |
| Rolf Srensen | Bavarian Nordic | N/A | |
| Jennifer Zonderman | BioPorto | N/A | |
| Russell Thirsk | Bavarian Nordic | N/A | |
| Niels Kristensen | cBrain AS | N/A | |
Management Performance
| Return On Equity | -0.89 | |||
| Return On Asset | -0.25 |
Nanologica AB Leadership Team
Elected by the shareholders, the Nanologica's board of directors comprises two types of representatives: Nanologica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nanologica. The board's role is to monitor Nanologica's management team and ensure that shareholders' interests are well served. Nanologica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nanologica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andreas Bhagwani, Chief Officer | ||
| P Dutta, Sr Chromatography | ||
| Eva Osterman, Chief Officer | ||
| Gary Pitcairn, Chief Officer | ||
| AnnaKarin Renstrm, Chief Officer | ||
| Katarina Alenas, VP Chromatography |
Nanologica Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nanologica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.89 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (8.35) % | |||
| Current Valuation | 436.11 M | |||
| Shares Outstanding | 36.15 M | |||
| Shares Owned By Insiders | 61.81 % | |||
| Shares Owned By Institutions | 10.33 % | |||
| Price To Book | 44.50 X | |||
| Price To Sales | 87.40 X | |||
| Revenue | 12.91 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nanologica Stock Analysis
When running Nanologica's price analysis, check to measure Nanologica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanologica is operating at the current time. Most of Nanologica's value examination focuses on studying past and present price action to predict the probability of Nanologica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanologica's price. Additionally, you may evaluate how the addition of Nanologica to your portfolios can decrease your overall portfolio volatility.